Swift Receives TGA Approval for Commercial Launch in Australia

Emblation has announced that the Swift® microwave system has received TGA approval, and is now available in Australia.

Briggate Medical Company, based in Melbourne, is the exclusive partner for Swift® in Australia. With more than 25 years in industry, Briggate Medical is a unique, family owned and managed company that specialises in supplying Australasia's private, hospital-based and community Podiatrists.

Emblation CEO, Gary Beale, commented: "We've had a great deal of interest from the Australian clinical community since research using the Swift® device began in 2013, so it's fantastic to finally deliver the first systems to the country. The support we've received from our commercial partners Briggate has been unparalleled, with their reputation and experience in the industry proving invaluable."

For all Australian enquiries, please visit briggatemedical.com. For enquiries in other countries, please visit our distributors page.

About Emblation

Emblation is a global leader in medical microwave technology, with a focus on radical innovation in the treatment of HPV infections, dermatology, cardiology, and oncology.

Established in the USA in 2007, the company relocated to Scotland the following year to continue research into novel microwave ablation products. The team is led by some of the world's foremost medical microwave experts, with a wealth of experience in the design, development and manufacture of microwave applications for a range of medical fields. Emblation is committed to providing next generation solutions for today's medical conditions.